Sangamo Therapeutics Inc. (NASDAQ:SGMO) changes shares on Tuesday trading session, with a change of -0.87% or -$0.1 shares. The trading starts at $11.47 and closed at $11.54 throughout the day. The trading session low price was $11.28 and day high was $11.61 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 1.22 million while its average volume is 2.26M. In other hand, the SGMO market cap reached to $1.69B.
On June 18, 2020, Pfizer’s hemophilia gene therapy shows sustained effect in early-stage study. According to the news reported on Reuters, Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does not clot easily.
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 14.06% and up 16.38% for month. Its quarterly performance was 30.59% above, while its half year performance is up 54.80%. SGMO yearly performance stood at positive 1.60% and rise 36.68% for year-to-date. Current recommendation for Sangamo Therapeutics Inc. is 2.20.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. SGMO EPS (TTM) for 12-month is -0.83. EPS for this year is -20.40%, while for the next year its value is -1.32. Its EPS Q/Q reached 10.30%. It has an EPS of -16.60% down for past five years.
Let’s take a look on the analyst recommendations on SGMO for the current month and previous month. For the current month, 6 of 9 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 3 as Hold. As compared with the previous month ratings, 8 analysts participate in stock recommendation. Out of 8, 0 rated it sell, 5 rated it as Buy and 3 as Hold Ratings. On the other hand, target price ranges from $11.00 – $36.00. Average target price for SGMO was reached at $21.50.
Blackrock Inc., Vanguard Group, Inc. (The) and Wasatch Advisors Inc are the top three holders in Sangamo Therapeutics Inc. (SGMO) stock. On Mar 30, 2020, Blackrock Inc. has 9.38 million shares which valued 59.73 million. On Mar 30, 2020, Vanguard Group, Inc. (The) owned 8.55 million shares which valued at 54.49 million. On Mar 30, 2020, Wasatch Advisors Inc has a total of 5.94 million shares which valued at 37.83 million. In the end, Wasatch Advisors Inc have 4.22% shares outstanding of Sangamo Therapeutics Inc. (SGMO) on Mar 30, 2020. The insider ownership moved to 0.60% and institutional holding shifted to 54.00%.
The company posted an EPS (TTM) of -0.83. According to the most recent quarter report on (Jun 2020), 9 analysts estimated an average EPS of 0.07, while -0.26 EPS posted a year ago period. Analyst Estimated EPS for SGMO published in the report was -$0.45 – $2.02 during the same period. Comparing with last year, the average estimated EPS was -0.26 which is higher than -0.37 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for SGMO rise 28.63% for period of 200 days. SMA for 50 days was 7.88% which is showing green signal, while SMA-20 was 5.27%. The moving average value for Sangamo Therapeutics Inc. (SGMO) is 17.1M and 13.17% for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in SGMO stock. On Mar 19, DILLY STEPHEN GEORGE, Director, sold 35,000 trading shares at the cost of $6.00, which valued at 0.21 million. On Mar 18, PARKER H STEWART, Director, bought 3,000 shares at the cost of $5.20, with total shares of 13,000. On Mar 17, Zakrzewski Joseph S, Director, bought 5,000 shares at the cost of 4.99. After this transaction, Zakrzewski Joseph S total shares reached to 30,000 which valued at 24950.0.